The opportunity
Advance patient care in gynecologic oncology as an Associate Medical Director at Natera. In this clinical leadership role, you will direct medical strategy and clinical development for our advanced cell-free DNA (cfDNA) and liquid biopsy portfolio, focusing on minimal residual…
What you'll do
Partner with the Sr. Medical Director, Oncology on the clinical development: of cell-free DNA (cfDNA) molecular diagnostics and liquid biopsy assays for gynecologic cancers.
Direct the development and execution of clinical strategies and: evidence-generation plans that demonstrate clinical utility in gynecologic oncology, including minimal residual disease (MRD) tracking, recurrence monitoring, treatment response assessment, and clinical trial enrichment.
Oversee medical education and scientific communications for healthcare: providers focused on gynecologic oncology, including tumor boards, webinars, and field medical enablement.
Partner with commercial and marketing teams to deliver clear, data-driven: clinical evidence and educational materials to gynecologic oncology stakeholders, including gynecologic oncology surgeons, medical oncologists, pathologists, radiation oncologists, genetic counselors, and advanced practice providers.
Represent Natera at medical congresses and industry events, including SGO,: ASCO, and ESMO, both in person and virtually.
Build and maintain relationships with external experts, clinical: investigators, cooperative groups such as NRG/GOG, and professional societies within gynecologic oncology.
What they're looking for
- Maintain a standard of scientific rigor and data-driven urgency across the oncology organization.
- Collaborate with R&D, biostatistics, clinical operations, and HEOR on: protocol development, endpoint selection, data analysis, data interpretation, peer-reviewed publications, and congress submissions in gynecologic oncology.
- Support investigator-initiated research, real-world evidence generation, and: clinical collaborations that advance the standard of care in gynecologic cancers.
- Deep knowledge of gynecologic malignancies, including current treatment: paradigms, molecular biomarkers such as HRD, MSI/Lynch, and HPV-related disease, and evolving clinical guidelines.
